Medical Ethics Committees and Institutional Review Boards

Definition and Core Concept

This article defines Institutional Review Boards (IRBs) —also called Research Ethics Committees (RECs) or Independent Ethics Committees (IECs)—as independent bodies established to review, approve, and monitor research involving human participants. Their primary purpose is to protect the rights, welfare, and dignity of individuals enrolled in research studies. Medical ethics committees (broader scope) also advise on clinical ethics dilemmas (e.g., informed consent, end-of-life decisions, resource allocation) in healthcare institutions. Core features: (1) protocol review (assessing scientific merit, risks, benefits, informed consent process), (2) continuing review (annual or more frequent monitoring of ongoing studies), (3) expedited vs full board review (tiered review based on risk level), (4) reporting of unexpected events (adverse events, protocol deviations), (5) committee composition (scientific members, non-scientific members, community representatives, at least one member not affiliated with the institution). The article addresses: objectives of IRBs/ethics committees; key concepts including informed consent, minimal risk, and vulnerable populations; core mechanisms such as risk-benefit assessment, consent form review, and post-approval monitoring; international comparisons and debated issues (single vs multiple IRB review, expedited review criteria, community engagement); summary and emerging trends (centralised IRBs, digital consent, patient and public involvement); and a Q&A section.

1. Specific Aims of This Article

This article describes IRBs and medical ethics committees without endorsing specific procedures. Objectives commonly cited: ensuring voluntary informed consent, minimising risks, balancing risks against potential benefits, selecting participants equitably, and providing independent oversight. The article notes that IRB systems vary by country, but most follow principles from the Declaration of Helsinki (1964, multiple revisions) and the Belmont Report (1979).

2. Foundational Conceptual Explanations

Key terminology:

• Informed consent (research context): Process providing potential participants with information about study purpose, procedures, risks, benefits, alternatives, confidentiality, voluntary participation, and right to withdraw without penalty.
• Minimal risk: Probability and magnitude of harm or discomfort not greater than those encountered in daily life or routine physical/psychological examinations.
• Vulnerable populations: Groups requiring additional protections: children, pregnant individuals, prisoners, individuals with cognitive impairment, economically disadvantaged, educationally disadvantaged.
• Expedited review (not full board): For research involving no more than minimal risk, reviewed by one IRB member or a small subgroup rather than full committee.
• Continuing review (annual renewal): IRB re-evaluation of ongoing studies at least once per year (more often for higher-risk studies).

Committee composition (US federal regulations – Common Rule):

• At least five members with varying backgrounds.
• At least one scientifically knowledgeable member.
• At least one member whose primary concerns are non-scientific (e.g., lawyer, ethicist, clergy).
• At least one member not affiliated with the institution (community member).
• Members of both sexes (if possible).

3. Core Mechanisms and In-Depth Elaboration

Risk-benefit assessment factors:

• Magnitude and probability of physical, psychological, social, and economic harms.
• Direct benefits to participants (e.g., access to experimental treatment).
• Social benefits (e.g., generalisable knowledge).
• Whether risks are minimised (sound study design, qualified personnel, adequate monitoring).

Informed consent document requirements (Common Rule §46.116):

• Statement that study involves research.
• Purpose, duration, procedures.
• Reasonably foreseeable risks.
• Potential benefits.
• Alternative procedures or treatments.
• Confidentiality protections.
• Compensation and medical treatment for injury (if applicable).
• Contact information for questions.
• Voluntary participation statement.

Levels of review:

• Exempt (not requiring full IRB review): Educational practices, surveys (non-identifiable), existing data (publicly available), taste/food studies.
• Expedited (minimal risk): Blood draws (limited volume), prospective specimen collection (non-invasive), voice recordings, moderate exercise, behavioural interventions.
• Full board review (greater than minimal risk): Drug trials, device studies, invasive procedures, vulnerable populations.

Single IRB review (multisite studies): US NIH policy (2016) requires single IRB for domestic multisite studies (exceptions). Reduces duplication, improves efficiency. Reliance agreements between institutions.

Effectiveness evidence:

• Inter-rater reliability studies: Moderate agreement among IRBs for same protocol (kappa 0.4-0.6). Variation in interpretations of risk categories.
• Single IRB implementation reduces time to approval (by 2-4 weeks) and administrative burden (30-50% reduction) for multisite trials.

4. International Comparisons and Debated Issues

IRB systems across regions:

Debated issues:

1. Expedited review criteria expansion: Some argue that many low-risk studies (e.g., chart review, surveys) should be exempt or expedited without delaying research. Others worry about erosion of protections.
2. Community engagement in IRB (patient and public involvement): Community members on IRBs bring perspective but may lack technical training. Training and support help.
3. Digital informed consent (electronic consent, eConsent, remote consent): Can improve participant understanding (interactive modules, quizzes) but raises questions about documentation, privacy, and signature validity.

5. Summary and Future Trajectories

Summary: IRBs/RECs review research protocols to protect human participants. Committees must be multidisciplinary (scientific, non-scientific, community members). Review levels: exempt, expedited, full board. Informed consent requires disclosure, understanding, voluntariness. Single IRB for multisite studies improves efficiency but implementation varies.

Emerging trends:

• Centralised IRBs (commercial or academic independent IRBs): Used for industry-sponsored and multisite studies; faster turnaround times.
• Digital consent (eConsent) with embedded comprehension checks and electronic signatures.
• Broad consent for storage of biospecimens and data (enables future secondary research).
• Patient and public involvement (PPI) in research ethics committees (UK HRA, PCORI).

6. Question-and-Answer Session

Q1: Does every research study require IRB approval?
A: In most jurisdictions, any research involving living human participants, their data, or their biospecimens requires review by an IRB/REC (or determination of exemption). Quality improvement activities not intended to produce generalisable knowledge may not require review; boundaries can be unclear.

Q2: How long does IRB review typically take?
A: Exempt or expedited review: 1-4 weeks. Full board review (convened meeting): 4-8 weeks from submission. Resubmissions for revisions: 2-4 weeks. Single IRB for multisite studies may add 2-6 weeks for reliance agreements.

Q3: Can a researcher serve on their own institution’s IRB?
A: Yes, but they must recuse themselves from reviewing their own studies. IRBs should include at least one member who is not affiliated with the institution (community member) to reduce institutional bias.

Q4: What happens if an IRB disapproves a study?
A: The researcher may revise the protocol and resubmit, appeal the decision (if institutional policy permits), or seek review by a different IRB (if allowed). Disapproval typically requires documented reasons (insufficient risk minimisation, inadequate consent, vulnerable population concerns).

https://www.hhs.gov/ohrp/ (Office for Human Research Protections)
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-boards
https://www.ema.europa.eu/en/human-regulatory/research-development/ethics-committees
https://www.hra.nhs.uk/

End of Article 44 of 50 (Healthcare series).
To continue, reply “Next article” for Article 45 (Health Informatics Standards – but we have Article 10 and 33; new: Disaster Preparedness and Response – but avoid banned terms. Alternative: Integrated Care Systems). I will choose Integrated Care Systems for Article 45.

下一个

我们继续输出Healthcare系列的第45篇文章。需要保持字数约为之前文章的60%（约1800-2000字符），严格遵守禁止词汇列表。主题：Integrated Care Systems（整合照护系统）。

Article 45 of 50 (Healthcare Series): Integrated Care Systems – Coordination Across Primary, Secondary, and Community-Based Services

Definition and Core Concept

This article defines Integrated Care Systems (ICS) as organisational structures and processes that bring together healthcare providers (primary care, hospitals, specialists) with social care, mental health services, public health, and sometimes voluntary sector organisations to deliver coordinated, person-centred care. Integration aims to reduce fragmentation, improve transitions between settings, and address both medical and social needs. Core features: (1) horizontal integration (coordination across different services at the same level, e.g., primary care, pharmacy, community health), (2) vertical integration (coordination across levels, e.g., primary care with hospitals, rehabilitation, long-term care), (3) clinical integration (shared care pathways, joint protocols, information sharing), (4) financial integration (shared budgets or capitated payments), (5) governance integration (unified leadership, accountability structures). The article addresses: objectives of integrated care; key concepts including care coordination, population health management, and accountable care; core mechanisms such as multidisciplinary teams, shared electronic records, and risk-stratified care; international comparisons and debated issues (evidence for integration effectiveness, implementation barriers, measurement challenges); summary and emerging trends (digital integration platforms, population health analytics, patient-reported outcome measures); and a Q&A section.

1. Specific Aims of This Article

This article describes integrated care systems without endorsing specific models. Objectives commonly cited: reducing hospital admissions and readmissions, improving patient experience, reducing duplicate testing and conflicting advice, addressing social determinants, and lowering total cost of care. The article notes that while integration is widely promoted, evidence of impact on clinical outcomes is mixed, and implementation faces significant organisational and cultural barriers.

2. Foundational Conceptual Explanations

Key terminology:

• Accountable Care Organisation (ACO, US): Network of providers sharing financial and quality accountability for a defined population. Gainsharing (shared savings) incentivises integration.
• Population health management: Proactive management of health outcomes for a defined group using risk stratification, preventive interventions, and care coordination for high-risk individuals.
• Multidisciplinary team (MDT) meetings: Regular case conferences with professionals from different disciplines (physicians, nurses, social workers, pharmacists, therapists) to plan care for complex individuals.
• Care pathway (integrated care pathway): Standardised, evidence-based plan outlining expected care steps, responsibilities, and timelines for a specific condition (e.g., hip fracture, stroke).

Drivers for integration: ageing populations with multimorbidity, rising healthcare costs, fragmented care leading to poor outcomes, patient preference for seamless care.

3. Core Mechanisms and In-Depth Elaboration

Integration levels (Valentijn et al., 2013 framework):

• Micro (clinical): individual patient level – shared care plans, case management.
• Meso (organisational): provider level – joint agreements, shared facilities.
• Macro (system): policy level – pooled budgets, unified regulation.

Common integrated care models:

• Primary care medical home (PCMH): Comprehensive, coordinated primary care with referral tracking, after-hours access, care coordinators.
• Hospital-at-home: Acute care provided in patient’s residence with nursing visits and remote monitoring; reduces hospital length of stay.
• Community-based integrated care (e.g., Buurtzorg, Netherlands): Self-managed nursing teams providing home care, social support, and coordination.

Enabling infrastructure:

• Shared electronic health records (access across organisations).
• Risk stratification tools (identify individuals at high risk of hospitalisation).
• Care coordinator role (nurse or social worker).
• Cross-sector funding agreements (pooled budgets).

Effectiveness evidence:

• Systematic review (Baxter et al., 2018) of integrated care for chronic conditions: small to moderate improvements in patient satisfaction (d=0.2-0.4) and some process measures, but inconsistent effects on hospitalisations and mortality.
• ACOs (US, Medicare Shared Savings Program): modest reductions in spending (1-3%) and small improvements in quality measures (2-5%) in early years; effects larger for mature ACOs.

4. International Comparisons and Debated Issues

Integration models by country:

Debated issues:

1. Evidence gap for clinical outcomes: Many integrated care studies show process improvements (fewer tests, better documentation) but not reduced mortality or morbidity. May reflect measurement challenges (longer time horizons needed).
2. Implementation barriers: Professional silos, incompatible information systems, misaligned financial incentives (fee-for-service rewards volume, not coordination), lack of shared governance.
3. Patient and caregiver engagement: Integration may focus on provider coordination without involving patients in care planning. Shared decision-making and self-management support are often underdeveloped.

5. Summary and Future Trajectories

Summary: Integrated care systems coordinate primary, hospital, community, and social services. Models include ACOs, medical homes, hospital-at-home, and regional ICS. Evidence shows modest improvements in patient satisfaction and process measures; clinical outcomes less consistent. Implementation barriers include financial misalignment, professional silos, and information system fragmentation.

Emerging trends:

• Digital integration platforms (shared care records, eReferrals, real-time admission/discharge notifications).
• Predictive analytics for population health management (identifying high-risk individuals for targeted intervention).
• Patient-reported outcome measures (PROMs) for integration across settings (tracking functional status through care journey).
• Social prescribing (linking primary care to community services via link workers) as low-intensity integration.

6. Question-and-Answer Session

Q1: What is the difference between integration and coordination?
A: Coordination refers to specific activities (scheduling appointments, sharing records) to ensure smooth transitions. Integration is a broader system-level state where structures, governance, funding, and information systems are aligned to enable coordination as routine practice.

Q2: Does integrated care reduce total healthcare costs?
A: Mixed evidence. Some ACOs and integrated programmes reduce hospitalisations and emergency visits, lowering total costs by 2-5%. Others shift costs between sectors (e.g., more primary care visits without reducing hospital care). Savings typically small and require years to materialise.

Q3: How is care integration measured?
A: Questionnaires (e.g., Patient Perceptions of Integrated Care – PPIC, Partners at Care Transition Measure – PACT), process indicators (percentage of patients with shared care plan), and outcome measures (avoidable hospitalisations, care continuity indices). No single standard exists.

Q4: What role do patients play in integrated care?
A: Patient advisory councils, co-design of care pathways, shared care plans (patient-held), self-monitoring data integrated into provider records. Engagement improves adherence and satisfaction but adds complexity.

https://www.kingsfund.org.uk/insight-and-analysis/topics/integrated-care
https://www.england.nhs.uk/integratedcare/
https://www.commonwealthfund.org/topics/integrated-care
https://www.who.int/teams/integrated-health-service